Cardiotoxicity of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia Therapy
Division of Hematology and Oncology, New York Medical College, Valhalla, NY 10595, USA
Department of Hematology, Institute of Hematology, Union Hospital, Fujian Medical University, Fuzhou 350001, China
Author to whom correspondence should be addressed.
Hematol. Rev. 2009, 1(1), e4; https://doi.org/10.4081/hr.2009.e4 (registering DOI)
Received: 13 January 2009
Revised: 6 March 2009
Accepted: 11 March 2009
Published: 13 March 2009
Emerging evidence suggests that the three tyrosine kinase inhibitors currently approved for the treatment of patients with chronic myelogenous leukemia (CML)—imatinib, dasatinib, and nilotinib—have potential cardiotoxic effects. The mechanisms behind these events, and the relations between them, are largely unclear. For example, relative to dasatinib and nilotinib, severe congestive heart failure and left ventricular dysfunction are rare but prominent with imatinib treatment, particularly in patients receiving higher doses (>600 mg/day). In comparison with imatinib, prolongation of the QT interval is relatively common in patients treated with either dasatinib or nilotinib. In contrast to nilotinib, pericardial effusions are observed with both imatinib and dasatinib. It is suggested that these data, an evaluation of cardiac status, use of concomitant medications, and potential risk factors should be considered in the management of CML.
Share and Cite
MDPI and ACS Style
Xu, Z.; Cang, S.; Yang, T.; Liu, D.
Cardiotoxicity of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia Therapy. Hematol. Rev. 2009, 1, e4.
Xu Z, Cang S, Yang T, Liu D.
Cardiotoxicity of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia Therapy. Hematology Reviews. 2009; 1(1):e4.
Xu, Zhenshu, Shundong Cang, Ting Yang, and Delong Liu.
2009. "Cardiotoxicity of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia Therapy" Hematology Reviews 1, no. 1: e4.
Article Access Statistics
Multiple requests from the same IP address are counted as one view.